{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:25:59Z","timestamp":1787199959472,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Collision tumors composed of colorectal adenocarcinoma and mantle cell lymphoma are exceptionally rare, and component-resolved molecular characterization is largely lacking. We report a 65-year-old woman who initially presented with rectal adenocarcinoma and underwent radical resection followed by adjuvant capecitabine. Seven months later, she developed generalized lymphadenopathy, and excisional cervical lymph node biopsy confirmed mantle cell lymphoma with Cyclin D1 and SOX11 positivity, t(11;14)(q13;q32) rearrangement, and a Ki-67 proliferation index of approximately 40%. Retrospective review of the original rectal resection specimen identified an occult mantle cell lymphoma component at the tumor margin and within the submucosa, leading to reclassification as a synchronous rectal collision tumor composed of adenocarcinoma and mantle cell lymphoma. Targeted sequencing across four specimens revealed a shared TP53 exon 7 frameshift in the archival composite rectal specimen, the rectal lymphoma component, and the adenocarcinoma component, whereas the nodal lymphoma specimen showed a dominant NOTCH2-truncating profile without a reported pathogenic TP53 alteration. The adenocarcinoma component additionally harbored a truncating APC alteration consistent with colorectal tumorigenesis. These findings support partial molecular overlap together with compartment- and site-specific divergence, while not establishing a common clonal origin. The patient received bendamustine plus rituximab followed by zanubrutinib maintenance and remained in remission at the last follow-up. This case highlights a clinically important diagnostic pitfall, shows how retrospective pathologic review can uncover occult gastrointestinal mantle cell lymphoma in a colorectal resection specimen, and provides multi-specimen molecular evidence of spatial heterogeneity across synchronous bowel and nodal disease.<\/jats:p>","DOI":"10.3389\/fonc.2026.1871711","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:39Z","timestamp":1787199339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Occult mantle cell lymphoma in a synchronous rectal collision tumor with adenocarcinoma: retrospective reclassification and multispecimen molecular profiling"],"prefix":"10.3389","volume":"16","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Xiu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Special Examination Center, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University","place":["Nantong, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028988","article-title":"Synchronous or collision solid neoplasms and lymphomas","volume":"101","author":"Parra-Medina","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i24.5772","article-title":"Synchronous rectal adenocarcinoma and intestinal mantle cell lymphoma: a case report","volume":"11","author":"Vu","year":"2023","journal-title":"World J Clin cases"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880395","article-title":"Early phase of intestinal mantle cell lymphoma: a report of two cases associated with advanced colonic adenocarcinoma","volume":"14","author":"Kanehira","year":"2001","journal-title":"Mod Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5858\/2003-127-E64-SAAMCL","article-title":"Synchronous adenocarcinoma and mantle cell lymphoma of the colon","volume":"127","author":"Padmanabhan","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000208899.15859.cb","article-title":"Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study","volume":"30","author":"Salar","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022354","article-title":"High-risk MCL: recognition and treatment","volume":"145","author":"Jain","year":"2025","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210280","article-title":"NOTCH signaling in mantle cell lymphoma: biological and clinical implications","volume":"24","author":"Deshotels","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14748","article-title":"Mechanism of APC truncation involved in colorectal cancer tumorigenesis (review)","volume":"29","author":"Wang","year":"2024","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2907272","article-title":"Unraveling the role of TP53 in colorectal cancer therapy: from wild-type regulation to mutant","volume":"29","author":"Li","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/359235a0","article-title":"APC mutations occur early during colorectal tumorigenesis","volume":"359","author":"Powell","year":"1992","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12030","article-title":"Clonal heterogeneity of mantle cell lymphoma revealed by array comparative genomic hybridization","volume":"90","author":"Liu","year":"2013","journal-title":"Eur J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","article-title":"TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant","volume":"41","author":"Sakhdari","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02942-1","article-title":"Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions","volume":"40","author":"Tavarozzi","year":"2026","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00277-026-06771-1","article-title":"TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma","volume":"105","author":"Liu","year":"2026","journal-title":"Ann Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103336","article-title":"Treatment outcomes for patients with newly diagnosed or relapsed\/refractory TP53-mutated mantle cell lymphoma: a systematic review and meta-analysis","volume":"85","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:44Z","timestamp":1787199344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1871711"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1871711","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1871711"}}